- Home
- ASMB vs SRV Comparison
ASMB vs SRV Comparison
Compare ASMB & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- SRV
- Stock Information
- Founded
- ASMB 2005
- SRV 2007
- Country
- ASMB United States
- SRV United States
- Employees
- ASMB N/A
- SRV N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- ASMB Health Care
- SRV Finance
- Exchange
- ASMB Nasdaq
- SRV Nasdaq
- Market Cap
- ASMB 196.9M
- SRV 193.1M
- IPO Year
- ASMB 2010
- SRV N/A
- Fundamental
- Price
- ASMB $27.47
- SRV $43.85
- Analyst Decision
- ASMB Strong Buy
- SRV
- Analyst Count
- ASMB 4
- SRV 0
- Target Price
- ASMB $42.33
- SRV N/A
- AVG Volume (30 Days)
- ASMB 156.9K
- SRV 33.9K
- Earning Date
- ASMB 11-06-2025
- SRV 01-01-0001
- Dividend Yield
- ASMB N/A
- SRV 13.38%
- EPS Growth
- ASMB N/A
- SRV N/A
- EPS
- ASMB N/A
- SRV N/A
- Revenue
- ASMB $33,247,000.00
- SRV N/A
- Revenue This Year
- ASMB $14.32
- SRV N/A
- Revenue Next Year
- ASMB N/A
- SRV N/A
- P/E Ratio
- ASMB N/A
- SRV N/A
- Revenue Growth
- ASMB 54.77
- SRV N/A
- 52 Week Low
- ASMB $7.75
- SRV $30.73
- 52 Week High
- ASMB $27.90
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- ASMB 65.33
- SRV 44.53
- Support Level
- ASMB $23.21
- SRV $44.12
- Resistance Level
- ASMB $27.17
- SRV $44.83
- Average True Range (ATR)
- ASMB 1.70
- SRV 0.90
- MACD
- ASMB 0.29
- SRV -0.26
- Stochastic Oscillator
- ASMB 97.82
- SRV 27.25
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.